Business Context and Reporting Period
This Form 8-K filing by IDEAYA Biosciences, Inc. (IDYA) reports a capital raise event occurring on January 22, 2024. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in South San Francisco, California.
Key Financial Metrics
The filing details a specific equity transaction rather than periodic financial performance metrics such as revenue or operating margins.
- Shares Sold: 3,119,866 shares of common stock.
- Net Proceeds: Approximately $126.9 million.
- Weighted Average Sales Price: Approximately $41.50 per share.
- Remaining Facility Capacity: Approximately $220.5 million available under the at-the-market offering program as of January 23, 2024.
Material Changes
The Company executed a sale of common stock under an Open Market Sales Agreement dated January 19, 2024, with Jefferies LLC. This transaction reduced the remaining capacity of the $350.0 million at-the-market offering program. The filing does not provide comparative financial data against prior periods as it is a current event report.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the equity offering. The transaction was conducted pursuant to an automatic shelf registration statement on Form S-3ASR.
Investor Verification Checklist
- Verify the final net proceeds after deducting sales agent commissions and offering expenses.
- Confirm the updated total share count and potential dilution impact on existing shareholders.
- Monitor future sales activity under the remaining $220.5 million facility capacity.
- Review the Company's use of proceeds in subsequent filings to ensure alignment with stated capital needs.